Abstract

Case Report

Granulomatosis with polyangiitis (GPA) in a 76-year old woman presenting with pulmonary nodule and accelerating acute kidney injury

Noor Sameh Darwich*, Melissa Schnell and L. Nicholas Cossey

Published: 20 January, 2020 | Volume 4 - Issue 1 | Pages: 001-006

Granulomatosis with polyangiitis (GPA), a form of ANCA-associated vasculitis (AAV), is a rare disease with an often-occult presentation. It is more common in 4th and 5th decades of life but can be seen in all ages.

This case report details a 76-year-old female presenting with abdominal pain, generalized weakness, and malaise, who was found to have pulmonary nodules on chest imaging. Biopsy of the lung nodule showed organizing pneumonia. Initially, antibiotics were used to treat the patient. However, she developed acute renal failure a few days after presentation and found to have positive serum C-ANCA as well as elevated ANCA-PR3 serologies. A subsequent kidney biopsy demonstrated pauci-immune necrotizing and crescentic glomerulonephritis that was consistent with GPA and the patient was started immediately on combination immunosuppressive therapy, plasmapheresis, and hemodialysis.

GPA’s clinical and radiological presentation can mimic other common conditions such as pneumonia, malignancy, bacterial sinusitis, pulmonary tuberculosis, sarcoidosis, and urinary tract infection. Because of this, a high level of suspicion is required for early diagnosis and treatment to alter the high mortality rate in this disease entity. All forms of ANCA-associated vasculitis (AAV) should be in the differential diagnosis for all patients presenting with multiorgan system involvement particularly in individuals with pulmonary and renal manifesations.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001048 Cite this Article Read Full Article PDF

Keywords:

GPA; ANCA-associated Vasculitides (AAV); Wegener granulomatosis

References

  1. Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DR, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011; 63: 863-864. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21374588
  2. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitis. Am J Med. 2004; 117: 39-50. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15210387
  3. Gomez-Puerta JA, Hernandez-Rodriguez J, Lopez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009; 136: 1101-1111. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19809051
  4. Jayne D. The diagnosis of vasculitis. Best Pract Res Clin Rheumatol.. 2009; 23: 445-453. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19508950
  5. Sedighi S, Aghaie M, Mozafari N, Roshandel G. Different features in Wegener’s Granulomatosis: report of five cases. Journal of Clinical and Diagnostic Research. 2011(Suppl-2), 5:1437-1439.
  6. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, et al. Efficacy of remission-induction regimens for ANCA- associated vasculitis. N Eng J Med. 2013; 369: 417-427. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23902481
  7. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, et al. Randomized trial of plasma exchange or High-dose methylprednisolone A adjunctive therapy for sever renal vasculitis. J Am Soc Nephrol. 2007; 18: 2180-218. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17582159
  8. Langford CA, Hoffman GS. Wegener’s granulomatosis. Thorax 1999; 54: 629-637. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1745525/
  9. Shafiei K, Luther E, Archie M, Gulick J, Fowler MR. Wegener’s granulomatosis: Case report and brief literature review. J Am Board Fam Pract. 2003; 16: 555-559. PubMed:
  10. Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I. Ocular manifestations of Granulomatosis polyangiitis: A review of the Literature. Ophthalmol Ther (2019) 8:227-234. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14963084
  11. Stewart C, Cohen D, Bhattacharyya I, Scheitler L, Riley S, et al. Oral manifestations of Wegener’s granulomatosis: a report of three cases and literature review. J Am Dent Assoc. 2007; 138: 338-348. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17332039
  12. Storesund B, Gran JT, Koldingsnes W. Severe intestinal involvement in wegener’s granulomatosis: report of two cases and review of the literature. Br J Rheumatol. 1998; 37: 387-390. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9619888
  13. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitidies: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005; 84: 115128. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15758841
  14. Miller PG, Santini C, Freed MJ. Dysphagia in a patient with Wegener's Granulomatosis: a Case report. Dysphagia. 2001; 16: 136-139. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11305224
  15. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, et al. 2012 revised international chapel Hill onsensus conference Nomenclature of vasculitides. Arthritis Rheum. 2013; 65: 1-11. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23045170
  16. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013; 123: 1773-1783. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23549081
  17. Schnabel A, Holl-Ulrich K, Dalhoff K, Reuter M, Gross WL. Efficacy of transbronchial biopsy in pulmonary vasculitidies. Eur Respir J. 1997; 10: 2738-2743. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9493653
  18. Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, et al. Management and treatment of glomerular Diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019; 95: 281-295; PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30665569
  19. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, et al. EULAR/ERA-EDTA recommendations for the Management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75: 1583-1594. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27338776
  20. Tesar V, Rihova Z, Jancova E, Rysava R, Merta M, et al. Current treatment strategies in ANCA-positive renal vasculitis: lessons from European randomized trials. Nephrol Dial Transplant. 2003; 18: Suppl 5: V2-V4. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12817056
  21. Charles P, Néel A, Tieulié N, Hot A, Pugnet G, et al. Rituximab for induction and maintenance treatment of ANCA-Associated vasculitides: a multicenter retrospective study on 80 patients. Rheumatology. 2014; 53: 532-539. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24282319
  22. Getha D, Kallenberg C, Stone JH, Salama AD, Appel GB, et al. Current therapy of Granulomatosis with polyangiitis and microscopic Polyangiitis: the role of rituximab. J Nephrol. 2015; 28: 17-27. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25185728
  23. Merkel PA, Kaplan AA, Falk RJ, Granulomatosis with polyangiitis and microscopic Polyangiitis: intial immunosuppressive therapy. UpToDate. 2020; 1-37.
  24. Jones RB, Furuta S, Tervaert JW. Rituximab versus cyclophosphamide in ANCA-Associated renal vasculitis: 2-year results of a randomized trial. Ann Rheum Dis. 2015; 74: 1178-1182. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25739829
  25. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. American Journal of Kidney Diseases 2003; 42: 1149-1153. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14655185
  26. Walsh M, Merkel PA, Jayne. The Effects of Plasma Exchange and reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Sever ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2018: 70 (Suppl 10). https://acrabstracts.org/abstract/the-effects-of-plasma-exchange-and-reduced-dose-glucocorticoids-during-remission-induction-for-treatement-of-sever-anca-associated-vasculitis/
  27. Hogan SL, Folk RJ, Chin H, Cai J, Jennette CE, et al. Predictors of relapse and treatment resistance in Antineurtophil Cytoplasmic Antibody-Associated Small-vessel Vasculitis. Ann Intern Med. 2005; 143: 621-631. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16263884
  28. Popa ER, Trevaert JW. The relation between Staphylococcus aureus and Wegener’s Granulomatosis: Current knowledge and future Directions. Intern Med. 2003; 42: 771-780. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14518661
  29. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-Sulfamethoxazole(CO-TRIMOXAZOLE) for the prevention of relapses of Wegener’s granulomatosis. For the Dutch Co-Trimoxazole Wegener Study group. N Engl J Med. 1996; 335: 16-20. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8637536
  30. Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020; 75: 124-137. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31358311
  31. Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, et al. CLEAR study Group. Randomized trial of C5a Receptor inhibitor Avocopan in ANCA-Associated Vasculitis. J AM Soc nephrol. 2017; 28: 2756-2767. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28400446
  32. Salvadori M, Tsalouchos A. Antineutrophil cytoplasmic antibody associated Vasculitides with renal involvement: Open challenges in the remission induction Therapy. World J nephrol. 2018; 7: 71-83. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29736379

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More